c-MET as a biomarker in patients with surgically resected non-small cell lung cancer

Hepatocyte Growth Factor (HGF) and its receptor cellular Mesenchymal Epithelial Transition factor (c-MET), a heterodimeric tyrosine kinase receptor, are frequently expressed in non-small cell lung cancer (NSCLC) and represents an oncogenic signaling pathway of major interest in NSCLC. c-MET protein overexpression, gene amplification and exon 14 splicing mutation (METex14) have been proposed as potential prognostic biomarkers as well as predictive biomarkers for targeted therapy, albeit their role in the clinical setting has not been firmly established yet [1,2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research